CTPs at a Crossroads: Navigating Regulation, Access, and Limb Preservation

1. Rapid Regulatory Catch-Up Is Reshaping the CTP Landscape 
Regulators are moving aggressively to rein in escalating CTP expenditures, introducing policies that could significantly restrict product utilization. While cost control is a legitimate concern, sudden pricing thresholds and coverage changes risk eliminating clinically valuable options. 

2. Physician Autonomy Is at Risk Amid Cost-Driven Policies 
A central concern is that product selection decisions—traditionally grounded in clinical judgment—could shift toward non-clinical regulators focused primarily on budget impact. This potential erosion of practitioner autonomy may ultimately affect limb preservation efforts and patient-specific wound outcomes. 

3. Lack of Clinical Education Is Driving Confusing and Sometimes Illogical Policies 
Inconsistent rules (eg, graft waste management policies and selective product regulation) highlight a disconnect between regulators and real-world wound care practice. Greater industry-led education is essential to ensure policymakers understand product differences, wound variability, and why treatment decisions must remain individualized. 

Please note: This content is a direct transcript, capturing the authentic conversation without edits. Some language may reflect the flow of live discussion rather than polished text. 

Well, the reality is that the landscape has evolved partially because the regulators are coming late to the game. It's not unique for CTPs, but the fact remains is that these things hit the market. Obviously, nobody really knew how much they were going to be utilized, how deep would dig into the costs of healthcare. But all of a sudden, we're seeing multi-billion dollar expenditures on CTPs, and the regulators suddenly said, “wait a minute.” We just can't keep writing blank checks. And so they're coming to the table now over the last year or so to try to backtrack, but these are the type of regulations that are trying to come in, and they can be draconian in a couple of ways because number one, if something suddenly doesn't fit into the price point, all of a sudden that product cannot be utilized, even though it might be the best product for the particular patient and the particular wound. 

But the other thing that's really concerning to me is there are an awful lot of people looking at this who we don't want (to have) the decision of which product is best for the patient. Which product should be used taken away from the physician, from the practitioner, and given to the regulators simply because of costs? And this is something that is fearful to me. It's not really happening yet, but you can see it coming as they try to reign in the costs of this. What is really making it difficult, I think, for a lot of practitioners is having to backtrack quite a bit in their approach. Now, I am not sitting here saying that every practitioner has got it down perfect. This is still in some ways, the wild West when it comes to these particular products and the utilization, and people are still learning. On the other hand, because regulations are coming in and because they're coming in from people that are not really educated in how to use them, the regulations coming in again, is causing backtracking or very honestly, sometimes just doesn't make sense. 

A perfect example is waste management. We now see that they're not going to pay if you use an eight centimeter graft and you only use four centimeters of it. Well, that suddenly puts a huge burden on a practitioner that may not be the best at measuring these things, which should come first, should the practitioner go back and learn better how to measure these things, or maybe the regulations need to be looked at a little closer so that we're not penalizing physicians who are not trying to do anything more than just treat the patient properly. It's this type of backtracking, it's this type of having to play catch up that I mentioned earlier, is really tying a lot of people's hands. Then of course, there's simply just the fact of the back and forth. We're going to regulate it all. Well, we're not going to regulate it all. 

Well, we're going to regulate most of it, but not the amnio products or only the amnio products. So there needs to be a consistent voice, and that really is where I think people are getting very confused. And again, we don’t want the practitioners’ medical decision-making being affected by non-medical people purely who have their eye on the bottom line. Well, what's going to hinder limb preservation efforts? What's going to tie the practitioner's hands again is decision making that's being done by people that are not educated. I keep mentioning education. It is so vital that we make sure that people that are making these decisions are educated properly. And I put this on industry because it's important for the people that are manufacturing that these CTPs who are absolutely meeting all the requirements when it comes to safety for the patient, et cetera, et cetera. But they need to educate the people that are overseeing this on the differences between the products, on the availability of why a practitioner is picking A versus B versus C or not using one at all. 

In this particular case, we know as practitioners that wounds come in a lot of different flavors. You're dealing with burns, you're dealing with trauma, you're dealing with non-trauma, vascular, avascular, et cetera. Do you use the same product on a venous ulcer that you use on an arterial ulcer that you use on a burn? But while we know this, why, we know this because of our medical education; the regulators don't know this, and so they're making decisions in a void, but don't be misled. They're still making decisions in the void, and that can tie a lot of people's hands, and more importantly, in my mind, can really affect a patient's outcome. 

Dr. Alper is a Trustee, on the Board of Trustees, of the American Podiatric Medical Association, and a Board Member of the American Diabetes Association, Northeast Region.